Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroCoil treatment for aneurysms to enter trials:

This article was originally published in Clinica

Executive Summary

Micrus is to begin US clinical trials of its minimally invasive treatment for intracranial aneurysms under an investigational device exemption from the FDA. The ACT MicroCoil delivery system releases coils into the aneurysm, which isolate it from arterial flow and reduce its chances of rupture or re-rupture. Rupture of intracranial aneurysms can lead to stroke and death if untreated, said the Mountain View, California based company. Micrus estimated that the worldwide market value of its product could be worth more than $100 million annually.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel